First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era.

about

Angiogenesis inhibitors for the treatment of small cell lung cancer (SCLC): A meta-analysis of 7 randomized controlled trials.

P2860

Q30235046-41102F3B-E823-477F-8770-E9F0BC56F1B2

P2860

First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era.

Item

http://www.wikidata.org/entity/Q38221293

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

First-line therapeutic options ...... in the molecular medicine era.

@en

type

Item

label

First-line therapeutic options ...... in the molecular medicine era.

@en

prefLabel

First-line therapeutic options ...... in the molecular medicine era.

@en

P1476

First-line therapeutic options ...... in the molecular medicine era.

@en

P2093

Enrica Capelletto

http://www.w3.org/2001/XMLSchema#string

Giorgio V Scagliotti

http://www.w3.org/2001/XMLSchema#string

Silvia Novello

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

ROS1 rearrangements define a unique molecular class of lung cancers.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

P304

1081-1093

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.13.247

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24941991

http://www.w3.org/2001/XMLSchema#string

First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era.

about

P2860

P2860

First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698